GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Cash Flow from Operations

Catalent (Catalent) Cash Flow from Operations : $250 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Catalent Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2024, Catalent's Net Income From Continuing Operations was $-101 Mil. Its Depreciation, Depletion and Amortization was $126 Mil. Its Change In Working Capital was $-101 Mil. Its cash flow from deferred tax was $3 Mil. Its Cash from Discontinued Operating Activities was $0 Mil. Its Asset Impairment Charge was $13 Mil. Its Stock Based Compensation was $17 Mil. And its Cash Flow from Others was $55 Mil. In all, Catalent's Cash Flow from Operations for the three months ended in Mar. 2024 was $12 Mil.


Catalent Cash Flow from Operations Historical Data

The historical data trend for Catalent's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Cash Flow from Operations Chart

Catalent Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 248.00 440.00 433.00 439.00 254.00

Catalent Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -64.00 196.00 -70.00 112.00 12.00

Catalent Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Catalent's Cash Flow from Operations for the fiscal year that ended in Jun. 2023 is calculated as:

Catalent's Cash Flow from Operations for the quarter that ended in Mar. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $250 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Catalent  (NYSE:CTLT) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Catalent's net income from continuing operations for the three months ended in Mar. 2024 was $-101 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Catalent's depreciation, depletion and amortization for the three months ended in Mar. 2024 was $126 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Catalent's change in working capital for the three months ended in Mar. 2024 was $-101 Mil. It means Catalent's working capital declined by $101 Mil from Dec. 2023 to Mar. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Catalent's cash flow from deferred tax for the three months ended in Mar. 2024 was $3 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Catalent's cash from discontinued operating Activities for the three months ended in Mar. 2024 was $0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Catalent's asset impairment charge for the three months ended in Mar. 2024 was $13 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Catalent's stock based compensation for the three months ended in Mar. 2024 was $17 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Catalent's cash flow from others for the three months ended in Mar. 2024 was $55 Mil.


Catalent Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Catalent's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalent (Catalent) Business Description

Traded in Other Exchanges
Address
14 Schoolhouse Road, Somerset, NJ, USA, 08873
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Executives
David Mcerlane officer: Group President, Biologics C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven Barg director ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
Michelle R Ryan director 214 PARK BLVD S, VENICE FL 34285
John J Greisch director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Frank A Damelio director C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Aristippos Gennadios officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Thomas W Hawkeswood officer: Pres. Pharma Prod Delivery Div C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Patricia Hunt officer: Pres. Consumer Health Div C/O CATALENT, 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson officer: VP, Chief Accounting Officer CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lorenzo Carletti officer: SVP Global Ops Small Molecule C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricardo Pravda officer: SVP, Human Resources C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli officer: See remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Charles Lickfold officer: SVP, CIO C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873